BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 20664599)

  • 1. Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer.
    Mori N; Kyo S; Nakamura M; Hashimoto M; Maida Y; Mizumoto Y; Takakura M; Ohno S; Kiyono T; Inoue M
    Br J Cancer; 2010 Sep; 103(6):889-98. PubMed ID: 20664599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.
    Mori N; Kyo S; Sakaguchi J; Mizumoto Y; Ohno S; Maida Y; Hashimoto M; Takakura M; Inoue M
    Cancer Sci; 2007 Dec; 98(12):1881-8. PubMed ID: 17924977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX; Xu XX; Tan BZ; Zhang Z; Zhou XD
    Cell Physiol Biochem; 2017; 41(3):933-946. PubMed ID: 28222438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hierarchical clustering of immunohistochemical analysis of the activated ErbB/PI3K/Akt/NF-kappaB signalling pathway and prognostic significance in prostate cancer.
    Koumakpayi IH; Le Page C; Mes-Masson AM; Saad F
    Br J Cancer; 2010 Mar; 102(7):1163-73. PubMed ID: 20216540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
    Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NEDD4 ubiquitin ligase is a putative oncogene in endometrial cancer that activates IGF-1R/PI3K/Akt signaling.
    Zhang Y; Goodfellow R; Li Y; Yang S; Winters CJ; Thiel KW; Leslie KK; Yang B
    Gynecol Oncol; 2015 Oct; 139(1):127-33. PubMed ID: 26193427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway.
    Dong P; Xu Z; Jia N; Li D; Feng Y
    Mol Cancer; 2009 Nov; 8():103. PubMed ID: 19917135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells.
    Gao J; Tian J; Lv Y; Shi F; Kong F; Shi H; Zhao L
    Cancer Sci; 2009 Mar; 100(3):389-95. PubMed ID: 19154413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel Impedes EGFR-mutated PC9 Cell Growth
    Mohiuddin M; Kasahara K
    Cancer Genomics Proteomics; 2021; 18(5):645-659. PubMed ID: 34479917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of long non-coding RNA OGFRP1 facilitates endometrial cancer by regulating miR-124-3p/SIRT1 axis and by activating PI3K/AKT/GSK-3β pathway.
    Lv Y; Chen S; Wu J; Lin R; Zhou L; Chen G; Chen H; Ke Y
    Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):2083-2090. PubMed ID: 31131636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of phosphorylated Akt, mTOR and MAPK in type I endometrial carcinoma: clinical significance.
    Kourea HP; Nikolaou M; Tzelepi V; Adonakis G; Kardamakis D; Tsapanos V; Scopa CD; Kalofonos C; Decavalas G
    Anticancer Res; 2015 Apr; 35(4):2321-31. PubMed ID: 25862896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination effects of paclitaxel with signaling inhibitors in endometrial cancer cells.
    Xu C; Li X; Li T; Wang X; Yang Y; Xiao L; Shen H
    Asian Pac J Cancer Prev; 2011; 12(11):2951-7. PubMed ID: 22393970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
    Wang Y; Gao C; Zhang Y; Gao J; Teng F; Tian W; Yang W; Yan Y; Xue F
    Gynecol Oncol; 2016 Oct; 143(1):168-178. PubMed ID: 27473926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogene alterations in endometrial carcinosarcomas.
    Biscuola M; Van de Vijver K; Castilla MÁ; Romero-Pérez L; López-García MÁ; Díaz-Martín J; Matias-Guiu X; Oliva E; Palacios Calvo J
    Hum Pathol; 2013 May; 44(5):852-9. PubMed ID: 23199529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
    Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
    Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRγ through AKT and ERK1/2.
    Sun Y; Wang C; Yang H; Ma X
    Eur J Cancer Prev; 2014 Sep; 23(5):418-24. PubMed ID: 25068805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer.
    Starska K; Forma E; Lewy-Trenda I; Stasikowska-Kanicka O; Skóra M; Bryś M
    Cell Oncol (Dordr); 2018 Jun; 41(3):253-268. PubMed ID: 29299828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
    Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
    Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer.
    Xu R; Nakano K; Iwasaki H; Kumagai M; Wakabayashi R; Yamasaki A; Suzuki H; Mibu R; Onishi H; Katano M
    Cancer Lett; 2011 Jul; 306(2):151-60. PubMed ID: 21429662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.